Abstract
We investigated the impact of Medicaid expansions made possible by the 2010 Affordable Care Act on HIV Pre-Exposure Prophylaxis (PrEP) utilization in the US over the period 2012–2018. We used data on PrEP utilization from Symphony Health in a difference-in-differences regression analysis with bootstrapped standard errors. We found that Medicaid Expansion resulted on average in 7.78 additional estimated PrEP users per 100,000 population on a yearly basis (z = 2.72; p = 0.007). When restricting the sample to males, Medicaid Expansion resulted in 14.67 additional PrEP users per 100,000 population each year (z = 2.5; p = 0.012). People in the age group 25–34 were those who benefitted the most from Medicaid Expansion with 16.95 additional PrEP users per 100,000 population per year attributable to Medicaid Expansion (z = 3.2; p < 0.001). States that are considering expanding Medicaid may recognize the benefits in PrEP utilization we document here.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Silvers JB. The Affordable Care Act: objectives and likely results in an imperfect world. Ann Fam Med. 2013;11:402–5.
Mahmoudi E, Cohen A, Buxbaum J. Gaining medicaid coverage during ACA implementation: effects on access to care and preventive services. J Health Care Poor Unders. 2018;29(4):1472–87.
Adams EK, Dunlop AL, Strahan AE. Prepregnancy insurance and timely prenatal care for medicaid births: before and after the Affordable Care Act in Ohio. J Women’s Health. 2018;28:654–64.
Wherry LR, Miller S. Early coverage, access, utilization, and health effects associated with the Affordable Care Act medicaid expansions. Ann Intern Med. 2016;164:795–803.
Hamman MK, Kapinos KA. Mandated coverage of preventive care and reduction in disparities: evidence from colorectal cancer screening. Am J Public Health. 2015;105:S508–16.
Zogg CK, Scott JW, Metcalfe D, et al. Association of medicaid expansion with access to rehabilitative care in adult trauma patients. JAMA Surg. 2019;154(5):402–11.
Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2014–2018. HIV Surveillance Supplemental Report 2020;25 (No. 1). https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2020. Accessed 29 July 2020.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.
Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.
Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV-1 prevention among heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
AIDSVu (aidsvu.org). Emory University, Rollins School of Public Health. Accessed 30 Jan 2020.
Centers for Disease Control and Prevention. HIV prevention pill not reaching most Americans who could benefit—especially people of color. Press Release. March 6, 2018.
Kazi DS, Katz IT, Jha AK. PrEParing to end the HIV epidemic—California’s route as a road map for the United States. N Engl J Med. 2019;381:26.
Craig T. The elusive end to HIV in the USA. Lancet. 2019;394(10215):2125.
Patel RR, Mena L, Nunn A, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS ONE. 2017;12(5):e0178737.
Rosenbaum S, Wilensky G. Closing the medicaid coverage gap: options for reform. Health Aff. 2020;39(3):514–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Approval
This research was not supported by grants or dedicated funding. Aggregated, state-level, de-identified, publicly available, secondary data were used for this research. The authors declare no competing interests in activities that would be affected by this research.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendix
Rights and permissions
About this article
Cite this article
Karletsos, D., Stoecker, C. Impact of Medicaid Expansion on PrEP Utilization in the US: 2012–2018. AIDS Behav 25, 1103–1111 (2021). https://doi.org/10.1007/s10461-020-03070-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-020-03070-2